Lupin introduces Honeywell Solstice Air inhalers for sustainable respiratory care

BENGALURU: Lupin is using Honeywell’s Solstice Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions.Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.“ By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,” said Vinita Gupta, CEO Lupin.“Solstice Air can play a critical role in ensuring that Lupin’s respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,” said Ashish Modi, President of Honeywell India. “By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions-reducing practices that support industry advancements.”